Company profile for Alder Biopharmaceuticals Inc

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Alder BioPharmaceuticals, Inc., is a clinical-stage biopharmaceutical company that discovers, develops and seeks to commercialize genetically engineered therapeutic antibodies with the potential to meaningfully transform current treatment paradigms. Alder’s lead pivotal-stage product candidate, eptinezumab, is being evaluated for migraine prevention. Eptinezumab is a monoclonal antibody that inhibits calcitonin gene-relat...
Alder BioPharmaceuticals, Inc., is a clinical-stage biopharmaceutical company that discovers, develops and seeks to commercialize genetically engineered therapeutic antibodies with the potential to meaningfully transform current treatment paradigms. Alder’s lead pivotal-stage product candidate, eptinezumab, is being evaluated for migraine prevention. Eptinezumab is a monoclonal antibody that inhibits calcitonin gene-related peptide (CGRP), a protein that is active in mediating the initiation of migraine.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
Alder BioPharmaceuticals, Inc. 11804 North Creek Parkway South Bothell, WA 980...
Telephone
Telephone
+425-205-2900
youtube
YouTube

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Default Event

DDL Conference

Not Confirmed

envelop Contact Supplier

DDL Conference

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.fiercepharma.com/pharma/alder-wanted-ex-u-s-partner-for-its-cgrp-drug-but-lundbeck-went-for-whole-thing

Angus Liu FIERCE PHARMA
25 Sep 2019

https://endpts.com/lundbecks-deborah-dunsire-didnt-just-want-an-ex-us-deal-for-alders-migraine-drug-she-wanted-the-whole-world/

John Carroll ENDPTS
24 Sep 2019
Lundbeck pens $2B Alder takeover to boost brain disease pipeline
Lundbeck pens $2B Alder takeover to boost brain disease pipeline

17 Sep 2019

// Nick P. Taylor FIERCE BIOTECH

https://www.fiercebiotech.com/biotech/lundbeck-pens-2b-alder-takeover-to-boost-brain-disease-pipeline

Nick P. Taylor FIERCE BIOTECH
17 Sep 2019

http://www.globenewswire.com/news-release/2019/07/08/1879405/0/en/Alder-BioPharmaceuticals-to-Showcase-14-New-Data-Presentations-Demonstrating-Eptinezumab-s-Migraine-Prevention-and-Quality-of-Life-Impact-at-American-Headache-Society-Meeting.html

GLOBE NEWSWIRE
08 Jul 2019
Amgen, Novartis file dueling lawsuits over Aimovig collaboration
Amgen, Novartis file dueling lawsuits over Aimovig collaboration

05 Apr 2019

// Eric Sagonowsky FIERCE PHARMA

https://www.fiercepharma.com/pharma/not-quite-a-year-into-launch-amgen-wants-to-can-its-aimovig-collaboration-novartis-lawsuit

Eric Sagonowsky FIERCE PHARMA
05 Apr 2019
Amgen launches TV spot for Aimovig in tight CGRP market
Amgen launches TV spot for Aimovig in tight CGRP market

17 Oct 2018

// Andrew Dunn BIOPHARMA DIVE

https://www.biopharmadive.com/news/amgen-launches-tv-spot-for-aimovig-in-tight-cgrp-market/539942/

Andrew Dunn BIOPHARMA DIVE
17 Oct 2018

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty